Sechs Fälle von Pityriasis rosea nach SARS-CoV-2-Impfung mit BNT162b2.

Ramot, Yuval; Nanova, Krassimira; Faitatziadou, Sofia-Maria; Assab, Dania Abu; Berkun, Yackov; Zlotogorski, Abraham

Ramot, Yuval; Nanova, Krassimira; Faitatziadou, Sofia-Maria; Assab, Dania Abu; Berkun, Yackov; Zlotogorski, Abraham.

Ramot Y; Department of Dermatology, Hadassah Medical Center, Hebrew University of Jerusalem, Faculty of Medicine, Jerusalem, Israel.
Nanova K; Clalit Health Services, Jerusalem, Israel.
Faitatziadou SM; Department of Dermatology, Hadassah Medical Center, Hebrew University of Jerusalem, Faculty of Medicine, Jerusalem, Israel.
Assab DA; Department of Dermatology, Hadassah Medical Center, Hebrew University of Jerusalem, Faculty of Medicine, Jerusalem, Israel.
Berkun Y; Department of Pediatrics, Hadassah Mount Scopus Medical Center, Hebrew University of Jerusalem, Faculty of Medicine, Jerusalem, Israel.
Zlotogorski A; Department of Dermatology, Hadassah Medical Center, Hebrew University of Jerusalem, Faculty of Medicine, Jerusalem, Israel.

J Dtsch Dermatol Ges ; 20(8): 1123-1125, 2022 08.

Article in English | MEDLINE | ID: covidwho-1992769

Subject(s)

COVID-19; Pityriasis Rosea; BNT162 Vaccine; Humans; Pityriasis Rosea/diagnosis; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pityriasis Rosea / COVID-19 Type of study: Diagnostic study Topics: Vaccines Limits: Humans Language: English Journal: J Dtsch Dermatol Ges Journal subject: Dermatology Year: 2022 Document Type: Article Affiliation country: Ddg.14784_g

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google